Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report – Research, Industry Analysis Reports and Market Demands

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Revenue
- 3.2.2 Top 3 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share in 2025
- 3.2.3 Top 6 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share in 2025
3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Overall Company Footprint Analysis
- 3.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Region Footprint
- 3.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Type Footprint
- 3.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value and Market Share by Type (2021-2026)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2021-2026)
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Application (2027-2032)

6 North America

6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2021-2032)
6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2032)
6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
- 6.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2021-2032)
- 6.3.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 6.3.3 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2021-2032)
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2021-2032)
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
- 7.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2021-2032)
- 7.3.2 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 7.3.3 France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 7.3.5 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 7.3.6 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region
- 8.3.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2021-2032)
- 8.3.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 8.3.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 8.3.5 India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 8.3.7 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)

9 South America

9.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2021-2032)
9.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2021-2032)
9.3 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
- 9.3.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
- 10.3.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)
- 10.3.4 UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
11.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
11.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Chain
12.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Upstream Analysis
12.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Midstream Analysis
12.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size was valued at US$ 2348 million in 2025 and is forecast to a readjusted size of US$ 5088 million by 2032 with a CAGR of 11.8% during review period.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The Duchenne muscular dystrophy (DMD) treatment market is primarily driven by the following factors:
I. Disease Burden and Unmet Needs
High Disability and Mortality Rates:
DMD is a progressive muscle wasting disease. Patients typically lose the ability to walk around age 10 and die from cardiopulmonary failure between the ages of 20 and 30. With approximately 300,000 cases worldwide and over 70,000 in China, the disease poses a significant social burden.
If a female carrier gives birth to a boy, there is a 50% chance that the child will inherit the disease, creating a high family genetic risk.
Limitations of Existing Treatments:
Current mainstream treatments, including corticosteroids (such as deflazacort) and topical exon-skipping drugs (such as Exondys 51), can only delay the disease, not cure it, and require long-term use with significant side effects.
There is a lack of universal treatments, which only cover specific gene mutation types (such as exon 51/53 skipping), limiting their applicable population. Improved Diagnosis Rate:
With improved medical infrastructure and urbanization, China's DMD diagnosis rate is expected to rise from approximately 30% in 2022 to over 50% in 2025, bringing more patients into the treatment-needing population.
II. R&D Progress and Pipeline Breakthroughs
Breakthroughs in Gene Therapy and Oligonucleotide Technologies:
Gene therapies, such as Sarepta's SRP-9001 (microdystrophin delivered via an AAVrh74 vector) and Faith Pharmaceuticals' BBM-D101 (engineered AAV vector), achieve long-term protein expression with a single dose. Clinical trials have shown a significant increase in the percentage of positive fibers.
Huida Gene's CRISPR-Cas12 gene editing therapy has entered clinical trials, targeting gene mutation repair.
Oligonucleotide therapies, including antisense oligonucleotides (ASOs) and next-generation peptide-coupled oligonucleotides (PPMOs), such as PepGen's PGN-EDO51 and Entrada's ENTR-601-44, enhance cellular uptake and lysosomal escape, improving efficacy and reducing dosage. Active Domestic R&D Pipeline:
Over 10 DMD drugs have entered clinical trials in China, including gene editing (such as Huida Gene's CRISPR-Cas12), AAV gene therapy (Jinwei Bio's JWK007), and mini-protein drugs (Faith Pharmaceuticals' BBM-D101). Some have received FDA orphan drug designation and are expected to be launched after 2026.
III. Policy Support and Optimized Payment Environment
Policy Support for Rare Diseases:
US: The DUX Act extends the market exclusivity period for DMD orphan drugs to 7.5 years, and the accelerated approval process shortens drug launch time by 34%.
China: DMD will be included in the second round of rare disease listings in 2024, promoting domestic R&D. Medical insurance coverage has expanded, with vamorolone included in the national medical insurance negotiations. The price of domestically produced gene therapies is expected to drop below 2 million yuan by 2026.
Improved Affordability:
North America: Commercial insurance companies (such as UnitedHealthcare) have prioritized DMD gene therapy reimbursement, with medical insurance coverage exceeding 80%. In Europe, reimbursement rates for products that pass HTA assessment exceed 80%, but product launches lag 9-15 months behind those in the US.
Asia-Pacific: Markets such as China, Japan, and South Korea are experiencing significant growth, with policies and capital jointly driving therapeutic accessibility.
The DMD therapy market is driven by disease severity, technological breakthroughs, and favorable policies. Gene editing and RNA therapies will dominate the future, but high costs and production capacity bottlenecks (such as AAV vector production) still need to be overcome. Companies need to focus on technological innovation and payment model optimization to address unmet medical needs.
This report is a detailed and comprehensive analysis for global Duchenne Muscular Dystrophy (DMD) Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts, in consumption value ($ Million), 2021-2032
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Duchenne Muscular Dystrophy (DMD) Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, ReveraGen BioPharma, Sperogenix, ReveraGen BioPharma Inc ., Belief BioMed, PTC Therapeutics, Santhera Pharmaceuticals, Italfarmaco, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Duchenne Muscular Dystrophy (DMD) Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Exondys
Emflaza
Translarna
Others
Market segment by Product Form
Hormonal Drugs
Exon Skipping
Small Molecule Drugs
Others
Market segment by Sales Channels
Online Sales
Offline Sales
Market segment by Application
Hospitals
Clinics
Home Care
Market segment by players, this report covers
Sarepta Therapeutics
ReveraGen BioPharma
Sperogenix
ReveraGen BioPharma Inc .
Belief BioMed
PTC Therapeutics
Santhera Pharmaceuticals
Italfarmaco
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Duchenne Muscular Dystrophy (DMD) Therapeutics, with revenue, gross margin, and global market share of Duchenne Muscular Dystrophy (DMD) Therapeutics from 2021 to 2026.
Chapter 3, the Duchenne Muscular Dystrophy (DMD) Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Duchenne Muscular Dystrophy (DMD) Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Duchenne Muscular Dystrophy (DMD) Therapeutics.
Chapter 13, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics research findings and conclusion.

Buy now